AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
226.08
-2.63 (-1.15%)
At close: Dec 5, 2025, 4:00 PM EST
226.45
+0.37 (0.16%)
After-hours: Dec 5, 2025, 7:55 PM EST
AbbVie Revenue
AbbVie had revenue of $15.78B in the quarter ending September 30, 2025, with 9.10% growth. This brings the company's revenue in the last twelve months to $59.64B, up 7.40% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$59.64B
Revenue Growth
+7.40%
P/S Ratio
6.71
Revenue / Employee
$1,084,436
Employees
55,000
Market Cap
399.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
ABBV News
- 1 day ago - Could Buying AbbVie Today Set You Up for Life? - The Motley Fool
- 2 days ago - AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 3 days ago - AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers - PRNewsWire
- 3 days ago - 2 Top Dividend Stocks to Buy Now and Hold For a Decade - The Motley Fool
- 4 days ago - AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating - Seeking Alpha
- 6 days ago - 3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years - The Motley Fool
- 6 days ago - Best Dividend Aristocrats For December 2025 - Seeking Alpha
- 7 days ago - SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance - GlobeNewsWire